VIRX (Viracta Therapeutics) Total Liabilities: $28.58 Mil (As of Sep. 2024)


What is Viracta Therapeutics Total Liabilities?

Viracta Therapeutics VIRX Total Liabilities is $28.58 Mil as of Sep. 2024.

Viracta Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 was $28.58 Mil.

Viracta Therapeutics's quarterly Total Liabilities declined from Mar. 2024 ($30.25 Mil) to Jun. 2024 ($28.65 Mil) and declined from Jun. 2024 ($28.65 Mil) to Sep. 2024 ($28.58 Mil).

Viracta Therapeutics's annual Total Liabilities increased from Dec. 2021 ($14.18 Mil) to Dec. 2022 ($34.89 Mil) and increased from Dec. 2022 ($34.89 Mil) to Dec. 2023 ($38.37 Mil).

Viracta Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Total Liabilities Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Liabilities
94.51 14.18 34.89 38.37

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.43 38.37 30.25 28.65 28.58

Viracta Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Viracta Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=38.373+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=38.37

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=56.692-18.319
=38.37

Viracta Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.575+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=28.58

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=21.958--6.617
=28.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $28.58 Mil mean?
Viracta Therapeutics (VIRX) has a Total Liabilities of $28.58 Mil as of Sep. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Total Liabilities too high?
Viracta Therapeutics' current Total Liabilities is $28.58 Mil.
How does Viracta Therapeutics' Total Liabilities compare to TSOI and CYTOF?
Viracta Therapeutics' Total Liabilities of $28.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Viracta Therapeutics and its competitors. Viracta Therapeutics's current Total Liabilities is $28.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Total Liabilities of $28.58 Mil. The current Total Liabilities is $28.58 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Total Liabilities is $28.58 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.